Control de la hipercolesterolemia en Españauna misma situación con diferentes realidades autonómicas

  1. Juan Pedro-Botet 1
  2. Núria Plana 2
  3. José María Mostaza 3
  4. Juan José Gómez-Doblas 4
  5. María Rosa Fernández Olmo 5
  6. Carlos Escobar Cervantes 6
  7. José Luis Díaz-Díaz 7
  8. Raquel Campuzano Ruiz 8
  9. Pedro Valdivielso 9
  10. Juan Cosín-Sales 10
  1. 1 Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España
  2. 2 Hospital Universitari Sant Joan, Reus, Tarragona, España
  3. 3 Hospital La Paz-Carlos III, Madrid, España
  4. 4 Hospital Universitario Virgen de la Victoria-IBIMA CIBERCV, Málaga, España
  5. 5 Hospital Universitario de Jaén, Jaén, España
  6. 6 Hospital Universitario La Paz, Madrid, España
  7. 7 Hospital Universitario A Coruña, A Coruña, España
  8. 8 Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
  9. 9 Hospital Virgen de la Victoria e IBIMA, Málaga, España
  10. 10 Hospital Arnau de Vilanova, Valencia, España
Mostrar afiliacións +
Revista:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168,  1578-1879

Ano de publicación: 2023

Volume: 35

Número: 5

Páxinas: 219-225

Tipo: Artigo

DOI: 10.1016/J.ARTERI.2023.04.001 DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Clínica e investigación en arteriosclerosis

Resumo

Introduction and objective: The cardiovascular prevention strategy by autonomous communities can be variable since the competences in health are transferred. The objective of the study was to determine the degree of dyslipidaemia control and the lipid-lowering pharmacological therapy used in patients at high/very high cardiovascular risk (CVR) by autonomous communities. Methods: Observational, cross-sectional, descriptive study based on a consensus methodology. Information on the clinical practice of 145 health areas belonging to 17 Spanish autonomous communities was collected through face-to-face meetings and questionnaires administered to the 435 participating physicians. Furthermore, aggregate non-identifiable data were compiled from 10 consecutive dyslipidaemic patients that each participant had recently visited. Results: Of the 4010 patients collected, 649 (16%) had high and 2458 (61%) very high CVR. The distribution of the 3107 high/very high CVR patients was balanced across regions, but there were inter-regional differences (P < .0001) in the achievement of target LDL-C < 70 and < 55 mg/dL, respectively. High-intensity statins in monotherapy or in combination with ezetimibe and/or PCSK9 inhibitors were used in 44, 21 and 4% of high CVR patients, while in those at very high CVR it rose to 38, 45 and 6%, respectively. The use of these lipid-lowering therapies at national level was significantly different between regions (P = .0079). Conclusions: Even though the distribution of patients at high/very high CVR was similar between autonomous communities, inter-territorial differences were identified in the degree of achievement of LDL cholesterol therapeutic goal and use of lipid-lowering therapy.

€ Ver financiamento

Información de financiamento

Financiadores

Fonte de datos: Dialnet